ABLE Member and Hyderabad-based Indian Immunologicals, a subsidiary of the National Dairy Development Board (NDDB), has launched 'Havisure', the first domestically developed Hepatitis A vaccine in India. Priced at ?2,150 per shot for the two-dose regimen, 'Havisure' represents a significant breakthrough in the nation's fight against Hepatitis A, a highly contagious viral infection transmitted through contaminated food or water.

With eight years of meticulous research and extensive clinical trials involving nearly 500 volunteers, 'Havisure' has emerged as a symbol of Atma Nirbhar Bharat (self-reliant India). Managing Director K. Anand Kumar emphasized the vaccine's efficacy and safety, highlighting its comparability with existing alternatives.

Manufactured at Indian Immunologicals' facility in Hyderabad, 'Havisure' aims to address both domestic and international markets, with plans for WHO pre-qualification underway. Targeting routine immunization and at-risk individuals such as travelers and those with occupational exposure, the vaccine promises to significantly reduce the burden of Hepatitis A nationwide.

This launch underscores Indian Immunologicals' commitment to advancing public health, following the successful introduction of measles, rubella, and TD vaccines earlier in the year. As India strives for self-sufficiency in vaccine production, 'Havisure' stands as a testament to the nation's scientific innovation and healthcare excellence.

Havisure' represents a significant breakthrough in the nation's fight against Hepatitis A, a highly contagious viral infection transmitted through contaminated food or water.